Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
186Re-labeled MAb U36
- Development stage
- Unknown
- Lead developer
- Janssen Biotech
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**186Re-labeled MAb U36** is an investigational CD44v6-targeted radioimmunotherapy for head and neck squamous cell carcinoma. The U36 monoclonal antibody binds the variant-6 epitope of CD44 on tumor cells and delivers the beta-emitting radionuclide rhenium-186 to targeted lesions, producing localized ionizing-radiation damage. A chimeric U36 radioimmunoconjugate was evaluated intravenously in a Phase 1 study in recurrent or metastatic head and neck squamous cell carcinoma; tumor targeting was observed, while dose-limiting myelotoxicity established the maximum tolerated activity. ([jnm.snmjournals.org](https://jnm.snmjournals.org/content/41/12/1999))
- Other names
- 186Re-U36rhenium-186-labeled MAb U36rhenium186-labeled MAb U36rhenium 186-labeled MAb U36
02
Targets
CD44v6 (CD44 variant isoform 6)
Beyond the preview
Go deeper on 186Re-labeled MAb U36.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 186Re-labeled MAb U36.